High Galectin-1 levels measured by gene expression profiling correlated with worse outcome in multiple myeloma, and knockdown of Galectin-1 in multiple myeloma cells resulted in smaller tumor formation and less lytic bone damage in an intra-tibeal injection model [10]. This evidence concerns the gene LGALS1 and neoplasm.